Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced ...

Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the ...

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Savara Inc. (NASDAQ:SVRA) was one of the ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the first quarter ending March 31, 2025, ...

The global economic and geopolitical environment in 2025 is marked by uncertainty, trade tensions, and shifting monetary ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Analysts at JMP believe that Molbreevi’s Breakthrough Therapy designation, compelling Phase 3 trial results, and the significant need for new aPAP treatments could lead to a Priority Review. With a ...

Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

In other recent news, Savara Inc. has completed its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential treatment for autoimmune ...

In other recent news, Savara Inc. has completed its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential treatment for ...

Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company focused on developing novel therapies for rare respiratory diseases, is approaching a critical juncture in its journey to bring its lead ...